摘要
目的探讨PET-CT在霍奇金淋巴瘤（HL）患者中的预后价值。方法回顾性分析50例初治HL患者资料。所有患者在一线治疗前、治疗中期或者治疗后接受氟脱氧葡萄糖F18（”F．FDG）PET-CT检查，采用SPSS13．0软件对患者生存进行分析。结果50例患者一线接受ABVD（多柔比星＋博来霉素＋长春新碱＋氮烯咪胺）或BEACOPP（博来霉素＋依托泊苷＋多柔比星＋环磷酰胺＋长春新碱＋甲基苄肼＋泼尼松）方案化疗。中位随访时间29．4（12．2～52．4）个月。接受中期、治疗后PET-CT检查的患者分别为35、46例。中期PET-CT阴性、阳性患者分别为25、10例，3年无进展生存（PFS）率分别为100％、70％，差异有统计学意义（e=-o．004）。治疗后PET-CT阴性、阳性患者分别为36、10例，3年PFS率分别为100％、60％，差异有统计学意义（P〈0．01）。结论治疗中期和治疗后PET-CT结果与HL患者PFS存在相关性，与总生存率的关系因随访时间过短不能确定。
Objective To determine the predictive value of interim and end-of-treatment ISF-FDG PET-CT after first-line treatment in patients with Hodgkin lymphoma （HL）. Methods The clinical data of 50 newly diagnosed HL patients were retrospectively analyzed. Baseline, interim and end-of-treatment PET-CT were performed, and then imaging results were analyzed for the survival of patients via software SPSS 13.0. Results Fifty patients received first-line treatment with ABVD （doxorubicin ＋ bleomycin ＋ vincristine ＋ dacarbazine） or BEACOPP （bleomycin ＋ etoposide ＋ doxorubicin ＋ cyclophosphamide ＋ vincristine ＋ procarbazine＋ prednisone） regimen. Interim PET-CT of 35 patients were performed after 2-4 cycles of treatment, 46 patients received PET-CT scans at the end of treatment. After a median follow-up of 29.4 months （ 12.2-52.4 months）, the 3-year progression-free survival （PFS） rates were 100% and 70% for the interim PET-CT negative （n=25） and positive （n=10） patients, respectively （P=-0.004）. The 3-year PFS rates were 100% and 60% for the post-treatment PET-CT negative （n=36） and positive （n=10） patients, respectively （P〈0.01）. Conclusion Interim and end-of-treatment PET-CT were correlated with 3-year PFS rates for HL patients. They may play an important role in predicting the outcome of HL. The relationship with OS can not be determined because of the short follow-up time.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2014年第4期325-327,共3页
Chinese Journal of Hematology
